SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced that Scott Oross has been appointed as General Counsel.
“I am pleased to welcome Scott to the Pipeline Therapeutics team. As a successful corporate attorney with a focus on the life sciences industry, Scott brings extensive experience across a range of business transactions and functions,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “We look forward to benefiting from his pragmatic advice, and believe that Scott will be an integral part of Pipeline’s success in the years to come.”
“I’m excited to be joining Pipeline, as the company furthers its two clinical programs in sensorineural hearing loss and multiple sclerosis, respectively,” said Scott Oross. “I look forward to working with Carmine and the rest of the team to advance the company’s portfolio of neuro-regenerative small molecules, with the aim of improving the current treatment options for currently underserved patients across multiple neurological disorders.”
Scott joins Pipeline Therapeutics with more than 20 years of experience in practicing law. Most recently, he served as a corporate partner with Sheppard Mullin Richter & Hampton LLP. Prior to that, he spent a majority of his career at Paul Hastings LLP, where he advanced from corporate associate to corporate partner. Scott received his J.D. from Vanderbilt University Law School where he was a John W. Wade Scholar. He received his B.A. in English and history from the University of Notre Dame.
About Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, including synaptogenesis, remyelination and axonal repair. The Company is seeking to alter the course of clinical disability experienced by patients with neurodegenerative diseases by reactivating innate repair pathways to restore function. Pipeline’s lead clinical program, PIPE-505, is in an on-going Phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The Company also has an ongoing Phase 1 healthy volunteer study for its second clinical program, PIPE-307, targeting multiple sclerosis. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions. For more information, please visit www.pipelinetherapeutics.com.